Corcept Therapeutics reports developments in cortisol modulation therapies for severe endocrinologic, oncologic, metabolic and neurologic disorders. The company markets Korlym for endogenous Cushing’s syndrome and Lifyorli, a relacorilant regimen approved with nab-paclitaxel for certain adults with platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.
Recurring news includes financial results, revenue guidance, clinical data from programs such as ROSELLA, DAZALS and MOMENTUM, FDA-related updates, medical-conference presentations, publications, patent matters and distribution arrangements tied to Korlym, Lifyorli and the company’s selective cortisol modulator pipeline.
Corcept Therapeutics (NASDAQ: CORT) reported strong Q2 2025 financial results with revenue of $194.4 million, up from $163.8 million in Q2 2024. The company modified its 2025 revenue guidance to $850-900 million due to specialty pharmacy capacity constraints amid surging demand. Net income was $35.1 million with cash and investments of $515.0 million.
Key developments include two NDAs in progress - one for hypercortisolism and another for platinum-resistant ovarian cancer, with relacorilant's PDUFA date set for December 30, 2025. The ROSELLA trial results were published in The Lancet, while the DAZALS trial showed an 84% reduction in death risk for ALS patients receiving dazucorilant. The company repurchased $115.4 million of common stock during Q2.
Corcept Therapeutics (NASDAQ: CORT) has scheduled its second quarter 2025 financial results announcement and corporate update for July 31, 2025. The company will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on the same day.
Participants must pre-register for the conference call to receive their unique access PIN and dial-in number. A listen-only webcast option will also be available, and a replay of the call will be accessible through the Investors / Events section of Corcept.com.
Corcept Therapeutics (NASDAQ: CORT) has submitted a New Drug Application (NDA) to the FDA for relacorilant, its selective cortisol modulator, to treat platinum-resistant ovarian cancer. The submission is supported by positive data from Phase 3 ROSELLA and Phase 2 trials, where relacorilant combined with nab-paclitaxel showed improved progression-free and overall survival compared to nab-paclitaxel alone.
The drug demonstrated a favorable safety profile, with adverse events comparable to nab-paclitaxel monotherapy. This marks Corcept's second NDA before the FDA, alongside relacorilant for hypercortisolism. The company is preparing for immediate commercial availability following potential regulatory approval.
Corcept Therapeutics (NASDAQ: CORT) announced significant results from its CATALYST trial of Korlym® in patients with hypercortisolism and difficult-to-control type 2 diabetes. The trial met its primary endpoint with patients receiving Korlym showing a 1.47% decrease in HbA1c compared to 0.15% in placebo group.
The study revealed that 24% of patients with difficult-to-control type 2 diabetes had hypercortisolism. Secondary endpoints were also met, with Korlym patients showing significant reductions in body weight (5.1 kg) and waist circumference (5.1 cm). Notably, patients receiving 900mg of Korlym demonstrated a 2.01% improvement in HbA1c.
The CATALYST trial, involving 1,057 patients across 36 U.S. sites, represents the largest and most rigorous study of its kind, with results simultaneously published in Diabetes Care.
Corcept Therapeutics (NASDAQ: CORT) has scheduled its first quarter financial results announcement and corporate update for May 5, 2025. The company will host a conference call on the same day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Key Conference Call Details:
- Participants must pre-register through a provided link
- Each registrant will receive a unique dial-in number and access PIN
- One PIN allows access for one caller
- A listen-only webcast option is available
- Call replay will be accessible through Corcept's website under Investors / Events tab
The Redwood City-based pharmaceutical company is maintaining transparency with investors through this scheduled financial disclosure and stakeholder communication event.
Corcept Therapeutics (NASDAQ: CORT) has announced it will present late-breaking data from its pivotal Phase 3 ROSELLA trial at the 2025 ASCO Annual Meeting. The study evaluates relacorilant plus nab-paclitaxel combination therapy versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer.
The presentation is scheduled for Monday, June 2, 2025, from 8:00 AM to 11:00 AM CDT as part of the Gynecologic Cancer Oral Abstract Session (Abstract Number: LBA5507). The ROSELLA trial is being conducted through a global collaboration with multiple oncology research groups, including GOG Foundation, ENGOT, APGOT, LACOG, and ANZGOG.
Corcept Therapeutics (NASDAQ: CORT) has published findings from the prevalence phase of its CATALYST trial in Diabetes Care journal, revealing that 24 percent of patients with difficult-to-control type 2 diabetes showed signs of hypercortisolism (Cushing's syndrome).
The study, the largest of its kind, screened 1,057 patients across 36 U.S. sites. All participants had hemoglobin A1c levels exceeding 7.5 percent despite receiving multiple glucose-lowering therapies, including GLP-1 receptor agonists. The screening was conducted using a standardized 1-mg dexamethasone suppression test (DST).
Part two of CATALYST, a randomized, double-blind, placebo-controlled study of Korlym® in patients with hypercortisolism and difficult-to-control type 2 diabetes, successfully met its primary endpoint of reduction in hemoglobin A1c. Complete results will be presented at the American Diabetes Association's 85th Scientific Sessions on June 23, 2025.